3. What Is DCIS?
• Malignant cell appearance
• Non-obligate precursor
• 15-50% progress to
invasive cancer
• ~20% upgrade rate
• ~15% autopsies
Wood JOP 2016 12;4;309-311
Cowell Mol Oncol 2013 7;5:859-869
4. • ~60,000 / year in U.S.
• Typical presentation is
calcifications on mgm
• Occasionally presents as
palpable mass
2009 NIH Consensus Conference
https://consensus.nih.gov/2009/dcisstatement.htm
7. Estrogen / Progesterone (ER/PR)
Receptors
• Estrogen binds to the receptor (present inside the cell) and
signals cell growth
• ER+(positive):
• Cancer cells have receptor, can be stimulated by estrogen
• ER- (negative):
• Cancer cells have lost the receptor, no response to estrogen
Normal Cell ER+ Cancer Cell ER+ Cancer Cell ER-
Estrogen Estrogen
8. Hormone Blockade
• Normal breast cells can develop abnormal growth when
exposed to estrogen
• Growth of ER/PR+ cancer cells stimulated by estrogen
• Reducing estrogen levels decreases risk of recurrence
Cancer Cell ER+
Tamoxifen
Estrogen Fat Cell
Hormone precursors
Aromatase
EstrogenPremenopausal women: tamoxifen
blocks ER receptor
Postmenopausal women: estrogen made in fat cells
Aromatase inhibitors block estrogen production
9. • Tamoxifen
• Blocks the estrogen receptor
• Pre- or post-menopausal
• 5 years
• Potential side effects:
•Hot flashes
•Vaginal discharge, ovarian
cysts, irregular bleeding
•Blood clots
•Uterine cancer (~4%,
average risk ~2%)
• Aromatase Inhibitors
•Anastrozole (Arimidex)
•Letrozole (Femara)
•Exemestane (Aromasin)
• Blocks production of
estrogen in the fat cells
• Postmenopausal only
• 5 years
• Potential Side effects:
•Hot flashes
•Bone loss / osteoporosis
•Joint pains
10. Why the Confusion?
• Not one disease
• Don’t agree on endpoint
•Overall survival
•Breast cancer specific survival
•Invasive vs in-situ recurrence
• Breast cancer specific survival
approaches 100% regardless of
treatment choice
Moran December 2015 ASCO Post
11. How To Decide?
•Treatment decisions require tradeoffs
•What endpoint most important to patients
•Can’t predict disease course
12. •Van Nuys Prognostic Index
•Patient Prognostic Index
•MSKCC Nomogram
•Oncotype Dx DCIS
•PreludeDx
13. • US Alliance COMET
• UK LORIS
• EORTC LORD
Clinical Trials
So clearly we have a range from indolent to aggressive behavior – DCIS is not one disease. It’s challenging because regardless of treatment, survival approaches 100%. It’s also challenging because we don’t all agree on the proper endpoint…
Prospective trials
Right now, we’re making assumptions based on the information we have – known biologic indicators such as grade and ER status, tumor size, patient age. But when we have a patient in front of us, we know we don’t have a crystal ball – we can’t predict if her indolent DCIS today will be the same in a few years. In the future, I expect that we will be acting on better biomarkers so we can get to that place of tailored or precision therapy for the individual patient